Tag: Rucaparib

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Rucaparib

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Added to Collection on: 2021-05-19 22:18:45

Tags for this article:

Organic compounds

Cancer

Clinical medicine

Click the tags to see associated articles and topics

View Article Details

PARP Inhibitors for Cancer Market to Witness Robust Expansion by 2028 - Stillwater Current

Added to Collection on: 2021-10-01 14:36:54

Tags for this article:

Chemical compounds

Organic compounds

PARP inhibitors

Heterocyclic compounds

Click the tags to see associated articles and topics

View Article Details

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy - - Pharmaphorum

Added to Collection on: 2022-03-14 02:54:15

Tags for this article:

Click the tags to see associated articles and topics

View Article Details

ImmunoGen Stock: Way Beyond SORAYA (NASDAQ:IMGN) | Seeking Alpha

Added to Collection on: 2022-04-10 16:07:43

Tags for this article:

Angiogenesis inhibitors

Breakthrough therapy

ImmunoGen

Progression-free survival

Bevacizumab

Rucaparib

Ovarian cancer

Click the tags to see associated articles and topics

View Article Details

Stock Traders Buy High Volume of Call Options on Clovis Oncology (NASDAQ:CLVS)

Added to Collection on: 2022-09-13 07:01:02

Tags for this article:

Click the tags to see associated articles and topics

View Article Details

PARP rivals close in on AZ and Merck's market leading Lynparza - - Pharmaphorum

Added to Collection on: 2022-10-04 18:29:25

Tags for this article:

Click the tags to see associated articles and topics

View Article Details

Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in ...

Added to Collection on: 2022-11-01 07:48:32

Tags for this article:

Tumor suppressor genes

Senhwa Biosciences Inc.

SAN DIEGO

Click the tags to see associated articles and topics

View Article Details

Allspring Global Investments Holdings LLC Sells 32149 Shares of Clovis Oncology (NASDAQ:CLVS)

Added to Collection on: 2022-11-04 08:21:24

Tags for this article:

Click the tags to see associated articles and topics

View Article Details

Urothelial Carcinoma Pipeline Landscape Analysis: 40+ Key Players & 50+ Pipeline Drugs

Added to Collection on: 2022-11-16 02:12:23

Tags for this article:

Transitional cell carcinoma

Transitional epithelium

Invasive urothelial carcinoma

Click the tags to see associated articles and topics

View Article Details

PARP Inhibitor Market Future Business Opportunities 2022-2028 - Digital Journal

Added to Collection on: 2022-12-25 16:37:35

Tags for this article:

Programmed cell death

DNA repair

Poly (ADP-ribose) polymerase

Olaparib

Market research

Rucaparib

Click the tags to see associated articles and topics

View Article Details

Tag: Rucaparib

Recent Related Articles to Rucaparib

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

PARP Inhibitors for Cancer Market to Witness Robust Expansion by 2028 - Stillwater Current

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy - - Pharmaphorum

ImmunoGen Stock: Way Beyond SORAYA (NASDAQ:IMGN) | Seeking Alpha

Stock Traders Buy High Volume of Call Options on Clovis Oncology (NASDAQ:CLVS)

PARP rivals close in on AZ and Merck's market leading Lynparza - - Pharmaphorum

Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in ...

Allspring Global Investments Holdings LLC Sells 32149 Shares of Clovis Oncology (NASDAQ:CLVS)

Urothelial Carcinoma Pipeline Landscape Analysis: 40+ Key Players & 50+ Pipeline Drugs

PARP Inhibitor Market Future Business Opportunities 2022-2028 - Digital Journal

Create dashboard for Tag: Rucaparib